445483-72-7

Basic information

• Product Name: ETHYL 3-(4-FORMYLPHENYL)PROPANOATE
• Synonyms: ETHYL 3-(4-FORMYLPHENYL)PROPANOATE;Benzenepropanoic acid, 4-formyl-, ethyl ester (9CI);4-FORMYL-BENZENEPROPANOIC ACID ETHYL ESTER;Ethyl 4-formylbenzenepropanoate;3-(4-Formylphenyl)propanoic acid ethyl ester
• CAS NO: 445483-72-7
• Molecular Formula: C₁₂H₁₄O₃
• Molecular Weight: 206.24
• Product Categories: ACIDHALIDE
• Mol File: 445483-72-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 317.9±17.0 °C(Predicted)
• Appearance: /
• Density: 1.103±0.06 g/cm3(Predicted)
• CAS DataBase Reference: ETHYL 3-(4-FORMYLPHENYL)PROPANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-(4-FORMYLPHENYL)PROPANOATE(445483-72-7)
• EPA Substance Registry System: ETHYL 3-(4-FORMYLPHENYL)PROPANOATE(445483-72-7)

Safety Data

• Hazardous Substances Data: 445483-72-7(Hazardous Substances Data)

Usage

General Description

Ethyl 3-(4-formylphenyl)propanoate is a chemical compound with the molecular formula C12H14O3. It is a yellowish liquid with a fruity odor and is commonly used as a flavoring agent in the food industry. ETHYL 3-(4-FORMYLPHENYL)PROPANOATE is also used in the production of pharmaceuticals and other organic compounds. It is synthesized by reacting ethyl acetoacetate with 4-formylbenzoic acid in the presence of a base catalyst. Ethyl 3-(4-formylphenyl)propanoate is known for its mild irritant properties and should be handled with care.

Upstream product

• 3054-95-3 acrylaldehyde diethyl acetal 
• 15164-44-0 p-(iodophenyl)carboxaldehyde 
• 539-74-2 Ethyl 3-bromopropionate 
• 1122-91-4 4-bromo-benzaldehyde 
• 104-88-1 4-chlorobenzaldehyde 
• 51828-89-8 ethyl 3‐(4‐formylphenyl)acrylate 
• 40640-98-0 3-(4-bromo-phenyl)-propionic acid ethyl ester 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 1044872-26-5 3-[4-(5,7-dimethoxy-4-oxo-3,4-dihydro-quinazolin-2-yl)-phenyl]-propionic acid ethyl ester 
• 1044870-77-0 3-(4-(5,7-dimethoxy-4-oxo-3,4-dihydroquinazolin-2-yl)phenyl)propanoic acid 
• 56703-35-6 ethyl 3-[4-(bromomethyl)phenyl]propanoate 
• 107859-98-3 ethyl 3-[4-(hydroxymethyl)phenyl]propanoate 
• 1338684-23-3 N-(3-{4-[(2,6-dimethylmorpholin-4-yl)methyl]phenyl}propyl)-4,5-dimethyl-2-nitroaniline 
• 1338684-25-5 3-{4-[(2,6-dimethylmorpholin-4-yl)methyl]phenyl}propan-1-ol 
• 1338684-24-4 ethyl 3-{4-[(2,6-dimethylmorpholin-4-yl)methyl]phenyl}propanoate 
• 1314881-44-1 3-[4-(1-amino-2,4-dicyanopyrido[1,2-a]benzimidazol-3-yl)phenyl]-N,N-dimethylpropanamide 
• 1314881-43-0 3-[4-(1-amino-2,4-dicyanopyrido[1,2-a]benzimidazol-3-yl)phenyl]-N-methylpropanamide 
• 1314881-75-8 3-[4-(1-amino-2,4-dicyanopyrido[1,2-a]benzimidazol-3-yl)phenyl]propanoic acid 
• 1314881-74-7 ethyl 3-[4-(1-amino-2,4-dicyanopyrido[1,2-a]benzimidazol-3-yl)phenyl]propanoate 
• 1314881-73-6 ethyl 3-(4-(2,2-dicyanovinyl)phenyl)propanoate 
• 34961-64-3 4-formyldihydrocinnamic acid 
• 81121-62-2 p-(3-hydroxypropyl)-benzaldehyde 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease

Simultaneous inhibition of phosphodiesterase 5 (PDE5) and histone deacetylases (HDAC) has recently been validated as a potentially novel therapeutic approach for Alzheimer's disease (AD). To further extend this concept, we designed and synthesized the first chemical series of dual acting PDE5 and HDAC inhibitors, and we validated this systems therapeutics approach. Following the implementation of structure- and knowledge-based approaches, initial hits were designed and were shown to validate our hypothesis of dual in vitro inhibition. Then, an optimization strategy was pursued to obtain a proper tool compound for in vivo testing in AD models. Initial hits were translated into molecules with adequate cellular functional responses (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation in the nanomolar range), an acceptable therapeutic window (>1 log unit), and the ability to cross the blood-brain barrier, leading to the identification of 7 as a candidate for in vivo proof-of-concept testing (Cuadrado-Tejedor, M.; Garcia-Barroso, C.; Sánchez-Arias, J. A.; Rabal, O.; Mederos, S.; Ugarte, A.; Franco, R.; Segura, V.; Perea, G.; Oyarzabal, J.; Garcia-Osta, A. Neuropsychopharmacology 2016, in press, doi: 10.1038/npp.2016.163).

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

HYPOPHOSPHOROUS ACID DERIVATIVES HAVING ANTIHYPERALGIC ACTIVITY AND BIOLOGICAL APPLICATIONS THEREOF

The invention relates to hypophosphorous acid derivatives of formula (I) wherein - X is H or OH, - R represents one or several radicals R1-R5, identical or different, two of R1-R5 optionally occupying the same position on the phenyl group, one to four of R1-R5 being H and the others being selected in the group comprising - 0-(CH2)n-COOH; - S-(CH2)n-COOH; -NH-(CH2)n-COOH; - 0-(CH,R') -COOH; -O- (CH2)n-OH; OR', -R' being a C1 -C3 alkyl radical;-OH; --COOH; halogen, particularly -F, - CI, -Br, -I, -CF3; -OCF3; -N02; -CH=CH-COOH; - -(CH2)n-COOH; O - (CH2)n- P03H2; O - (CF2)n- P03H2; O - (CH2)n- S03H; O - (CH2)n- CONHOH; O - (CH2)n-tetrazol; O - (CH2)n-hydroxyisoxazol - n = 1 to 5, preferably 1-3; said hypophosrous acid derivatives being diastereoisomers or enantiomers.